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Background: The purpose of this study was to compare the outcome, complications and survival of the commonly
used surgical reconstructions of the proximal humerus after intrarticular tumour resection in our hospital.
Methods: Between 1998 and 2010, 41 consecutive proximal humeral reconstructions using prosthesis (group P, n = 25)
or recycled pasteurized autograft combined with non-vascularised fibula autograft (group B, n = 16) were performed.
Results: The mean follow-up was 57.7 months. Fourteen patients (8 patients in group P and 6 in group B) died
during the follow-up period, the disease-specific survival of patients in group P was 74.5% at 5 years and in group B
was 67.0%. Local recurrences were occurred in 3 cases (12.0%) in group P and 2 (12.5%) in group B. Pulmonary
metastases were observed in 4 patients (16.0%) in group P and 4 (25.0%) in group B. There was no significant
difference in the incidence of local recurrence, pulmonary metastasis or death of disease. Revisions were indicated
in 9 patients (36.0%) in group P and 5 (31.25%) in group B. Thought the incidence of revisions was higher in group
P, there was no significant difference in these two groups. The Kaplan-Meier 5-year implant survival estimates, with
revision for any reason as the end point, were 80.6% and 68.8% for group P and group B, respectively. The mean
MSTS Score was 63.6% in group P and 63.0% in group B. These differences were not statistically significant.
Conclusions: The study could show that prosthetic reconstruction and reconstruction with recycled pasteurized
autograft are similar in terms of their local recurrence and metastasis, while the incidence of revisions was higher
for patients with prosthetic reconstruction.
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Malignant bone tumors of the proximal humerus are com-
mon, and multiple treatment options have been reported in
recent years [1-11]. In most cases, surgery comprises an
essential element of therapy. The clinical outcome, local
recurrence, and survival rates after limb-preserving and
other procedures seem to be comparable. To provide a
platform for elbow and hand function, reconstructive
limb-preserving procedures have been proposed for the
proximal humerus. Moreover, patient acceptance has
been described as higher for limb-preserving treatments.
Therefore, amputation of the shoulder girdle is avoided if
possible. In limb salvage procedures, large bone defects* Correspondence: zhangqing65230@126.com
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reproduction in any medium, provided the ormay result after resection of the proximal humerus. These
defects can be reconstructed with autograft, allograft,
implanted prostheses and composites [1-11].
Risks vary dependent on the choice of reconstruction.
Biological reconstruction can be complicated by fracture,
infection, and subchondral collapse, leading to implant re-
vision or removal [1-11]. Difficulties with endoprosthetic
reconstruction involve consequences of surgical resection
of deltoid and rotator cuff. These include proximal sub-
luxation, instability, and a reduction in functional range of
motion [1-11]. The aim of this study was to investigate
within a retrospective single center experience of surgi-
cally treated malignant bone tumors of the proximal hu-
merus, respective oncological, surgical, and functional
outcome differences after endoprosthetic and biologicalThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 1 Preoperative X-ray (AP view) of a 39-year male patient
with left humeral osteosarcoma.
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factors for appropriate indication.
Methods
Between the year 1998 and 2010, 47 patients at our insti-
tution were treated for primary malignant bone tumor of
the proximal humerus. Six of these 47 patients were lost
to follow-up, so 41 patients were included in this study.
There were 18 female and 23 male, with an average age
of 30.6 years (range, 18 to 45 years) at the time of oper-
ation. The mean duration of follow-up was 57.7 months
(range, 25 to125 months). Fourteen patients died during
the follow-up period. This study was approved by the
Second Xiangya Hospital committee for clinical research
and informed consent was obtained from the patients
participating in the study. The patients provided written
informed consent for the publication of individual clinical
details and accompanying images.
The histological diagnosis was osteosarcoma in 22
patients, Ewing’s sarcoma in 7, malignant fibrous histiocy-
toma in 9 and high-grade chondrosarcoma in 3. All these
cases of bone tumors were staged according to Enneking’s
criteria [12] with 19 stage IIA cases, and 22 stage IIB cases.
All the patients underwent wide en bloc intra-articular
excision and reconstruction of the defect with prosthesis in
25 cases (group P, see Figures 1 and 2) and biological means
in 16 cases (group B). In the present study, biological
reconstruction was used by recycled pasteurized auto-
graft combined with a non-vascularised fibula autograft
(see Figures 3, 4, 5 and 6). All patients with malignant
tumors except chondrosarcoma received preoperative
chemotherapies with a high dose of methotrexate, doxo-
rubicin and cisplatin.
Surgical technique
All patients were surgically treated by a single experienced
musculoskeletal oncologist (Q Zhang). Except in rare
instances in which biopsy sites or soft tissue extension of
tumor was prohibitive, an anterior transdeltoid approach
(paralleling the deltopectoral approach through the anter-
ior 1/5 of the deltoid) was used and biopsy tracks, when
present, were elliptically excised en bloc with the speci-
men. The humeral diaphysis was isolated and cut distally
using an wire saw at a point at least 2.0 cm from the distal
extent of the lesion. The lesion was measured on a coronal
MR image from the tip of the greater tuberosity, which
was localized intraoperatively through direct palpation or
observation. If possible, based on the length of resection,
the distal deltoid insertion was preserved. Cancellous
bone was curetted from the medullary canal distal to
the diaphyseal osteotomy and sent for intraoperative
frozen section to confirm a negative margin. The humerus
then was dissected circumferentially with a cuff of normal
muscle tissue. Except in rare instances in which priorsurgery or tumor proximity required sacrifice, the rotator
cuff was preserved and released from near its insertions
on the native humerus for later reattachment to the re-
construction. Likewise, the axillary nerve was preserved
when practical. No other major nerves were sacrificed
in any patient [1].
In group B, the mean length of the humeral defect
after excision of the tumor segment was 10.88 cm
(ranging from 8.0 to 13.5 cm). The bone was pasteurized
in the following manner. After resection of the bone, soft
tissue, gross tumor, and the intramedullary macroscopic
portion of the tumor were cleared thoroughly from the
specimen. It was then treated in saline, pre-heated at 65°C
for 30-60 minutes. The pasteurized bone combined with
a non-vascularised, autologous fibular graft were fixed
by a plate and screws. In group P, the endoprosthesis
used was a custom-made implant individually designed for
each patient to replace the proximal of humerus (Li Dakang
Co. Ltd, Beijng, China). The mean length of the humeral
excision was 10.98 cm (ranging from 8.3 to 13.5 cm).
For evaluation of endoprosthetic and biological recon-
struction methods, the two groups of patients were com-
pared regarding their oncological, surgical, and functional
outcome. For this, the post-operative events of infection,
fracture, aseptic loosening, and nonunion have been noted
Figure 2 Post operative X-ray (AP view) showing 39 months
follow-up of the same patient.
Figure 3 Preoperative X-ray (AP view) of a 35-year male patient
with right humeral malignant fibrous histiocytoma.
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come at latest clinical follow-up was evaluated apply-
ing the Musculoskeletal Tumor Society scoring system
(MSTS Score) [13]. The patients were examined clinic-
ally and radiologically every month during the first six
months after surgery to exclude the evidence of infec-
tion and local recurrence, every three months for the
following two years and then every six months. A CT
scan of the chest was performed every three months in
the first year and then every six months to exclude pul-
monary metastases. A bone scan was performed every
six months in the first year and then annually until the last
follow-up. Local recurrence was defined as re-occurrence
of a tumor throughout this protocol at least four months
after surgery.
Statistical analysis
SPSS v13.0 (SPSS Inc., Chicago, Illinois) was used to
perform the statistical analyses. Therapeutic variables
(revision and function), pathological variables (Enneking
stage, local recurrence and metastatic disease) and demo-
graphic variables (gender, age and duration of follow-up)
were examined. The endpoints of the study were local
recurrence, progression of disease and revision for any
cause. Descriptive summary statistics included means and
ranges. Age and time intervals were regarded as continuous
variables. All other covariates were modeled as categoricalvariables. Differences between means and proportions were
tested with the chi-squared test for categorical variables
and the t-test for continuous variables. All tests were two-
sided and a p-value < 0.05 was considered significant.
Results
The detailed description of the results of all 41 patients
were outlined in Table 1 and Table 2. The mean follow-up
of group P is 55.08 months while the mean follow-up of
group B is 61.75 months. In group B, all the patients had
achieved bony union at the last follow-up and the mean
time to graft union was 17.9 months (ranging from 12.5 to
27 month). Four patients (25.0%) acquired secondary
iliac crest cancellous bone grafting to achieve union
and one patient (6.25%) had a fracture because of slip-
ping to the ground. This was changed the internal fix-
tor and the fracture subsequently united uneventfully.
Figure 4 Preoperative MRI image of the same patient.
Figure 5 One week after reconstructions of the proximal humerus
after intrarticular tumour resection by recycled pasteurized
autograft combined with a non-vascularised fibula autograft.
Figure 6 Post operative X-ray showing adequate union of
the junction.
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group P and 2 cases (12.5%) in group B. The 5 patients
underwent subsequent amputation to treat their local
recurrence. Pulmonary metastases were observed in 4
patients (16.0%) in group P and 4 patients (25.0%) in
group B. Metastases were rated as irresectable due to
dissemination and treated by further chemotherapy.
These patients subsequently died of disease within
12 months. Table 3 summarizes the respective results and
incidences of the two treatment groups with prosthetic
and biological reconstruction. There was no significant
difference in the incidence of local recurrence, pulmonary
metastasis or death of disease (see Table 3). Superfical in-
fection occurred in 1 patient (4.0%) in group P, which was
resolved by debridements. There was no deep infection.
Chondrolysis occcured in all the patients in group B and
no treatment was required as painless in these patients.
Revisions were indicated in 9 patients (36.0%) in group
P and 5 patients (31.25%) in group B. The incidence of
revisions was higher for patients with prosthetic recon-
struction. However, there was no significant difference
regarding revision in these two groups (see Table 3). The
Kaplan-Meier 5-year implant survival estimates, with revi-
sion for any reason as the end point, were 80.6% and 68.8%
for the group P and group B, respectively (Figure 7). All pa-
tients were functionally assessed at latest follow-up. None
of the patients was able to abduct their shoulder more than
90°. The mean MSTS Score was 63.6% in group P and
63.0% in group B. These differences were not statistically
Table 1 Patients’ data of biological reconstruction










1 21/F Stage IIA 9.0 No Conservative (19) — 65 16.0 Death, 30
2 35/M Stage IIB 10.0 No No — 71 17.5 Alive, 125
3 27/F Stage IIB 9.5 No No Nonunion (1,13) 67 21.0 Alive, 109
4 23/F Stage IIA 11.0 No No — 62 15.0 Alive, 97
5 33/M Stage IIB 12.5 Amputation (21) Conservative (27) — 50 12.5 Death, 38
6 32/M Stage IIB 8.3 No No Nonunion (1,10) 63 18.0 Alive, 71
7 39/F Stage IIB 13.5 No No — 69 20.0 Alive, 85
8 31/M Stage IIA 12.0 No No Fracture (1,17) 60 27.0 Alive, 72
9 45/F Stage IIA 10.5 No Conservative (15) — 72 15.5 Death, 25
10 26/M Stage IIB 12.0 No No Nonunion (1,12) 58 19.0 Death, 67
11 38/F Stage IIB 9.5 No No — 67 13.5 Alive, 63
12 29/F Stage IIB 11.5 No No — 65 22.0 Alive, 56
13 30/M Stage IIA 12.0 No No — 55 18.0 Death, 50
14 42/M Stage IIA 11.5 No No Nonunion (1,12) 67 19.5 Alive, 42
15 28/M Stage IIB 9.7 Amputation (18) No — 52 16.0 Alive, 31



















Table 2 Patients’ data of prothesis








Revisions (number, months) MSTS score (%) Follow-up time
(months)
1 29/M Stage IIB 8.0 No No Aspetic loosening (1,68) 66 Alive, 120
2 37/M Stage IIA 9.5 No No Aspetic loosening (1,89) 73 Alive, 112
3 26/F Stage IIB 12.5 No No Aspetic loosening (1,76) 67 Alive, 105
4 18/M Stage IIB 13.0 No Conservative (20) — 65 Death, 27
5 24/M Stage IIB 13.5 No No — 65 Death, 76
6 41/F Stage IIA 10.3 No No Aspetic loosening (1,73) 71 Alive, 82
7 36/M Stage IIA 11.5 Amputation (16) No — 56 Death, 41
8 20/M Stage IIB 12.5 No No Aspetic loosening (1,66) 67 Alive, 75
9 32/M Stage IIB 12.8 No Conservative (25) — 60 Death, 34
10 28/F Stage IIA 10.5 No No Aspetic loosening (1,61) 62 Death, 69
11 31/F Stage IIB 8.5 No No — 67 Alive, 60
12 25/F Stage IIB 10.5 No No Aspetic loosening (1,50) 61 Alive, 57
13 38/M Stage IIB 10.0 Amputation (23) No — 51 Alive, 55
14 26/F Stage IIA 9.5 No No — 58 Alive, 50
15 32/F Stage IIA 11.0 No No — 63 Alive, 48
16 27/F Stage IIB 9.5 No Conservative (19) — 72 Death, 26
17 31/M Stage IIB 12.5 No No Aspetic loosening (1,43) 63 Alive, 47
18 38/M Stage IIA 11.0 No No — 64 Alive, 45
19 29/F Stage IIA 11.5 No No — 56 Alive, 41
20 31/F Stage IIA 9.5 No Conservative (32) — 67 Death, 35
21 23/M Stage IIB 10.2 No No Aspetic loosening (1,31) 62 Alive, 39
22 39/M Stage IIB 11.3 No No — 67 Alive, 36
23 27/F Stage IIB 10.0 Amputation (19) No — 53 Death, 32
24 25/M Stage IIA 12.5 No No — 70 Alive, 35























Total N = 25 N = 16 —
Mean age (years) 29.64 ± 5.99 32.19 ± 6.69 0.212a
Sex 13 M 9 M 0.790b
12 F 7 F
Mean follow-up (months) 55.08 ± 26.64 61.75 ± 30.42 0.464a
Ennecking’s Stage Stage IIA 11 Stage IIA 6 0.680b
Stage IIB 14 Stage IIB 10
Specimen Length (cm) 10.98 ± 1.51 10.88 ± 1.43 0.820a
Local recurrence 3 2 0.962b
Metastasis 4 4 0.478b
Mean MSTS 63.6 ± 5.65 63.0 ± 6.48 0.756a
Revision 9 5 0.754b
at-Test.
bChi-square-test.
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(8 patients in group P and 6 patients in group B) died of
their underlying disease, all other patients were alive with-
out evidence of disease at latest follow-up. Consequently,
the disease-specific survival of patients in group P was
74.5% at 5 years and in group B was 67.0% (Figure 8).
Discussion
The optimal reconstructive technique after proximal
humerus resection is controversial. There are several
literatures compared the outcome, complications andFigure 7 Kaplan-Meier implant survival curve subgroup analysis for t
surgery as end point.survival of different type of surgical reconstructions
after proximal humeral tumour resection [1-11]. Van de
Sande et al.’s [5] study showed that an endoprosthetic re-
construction after proximal humeral resection resulted
in the lowest complication rate, highest implant survival
and comparable functional results when compared to
allograft-prosthesis composite and osteoarticular allograft
use. Potter BK and his colleagues [1] stated that im-
plant revision was more common after osteoarticular
reconstruction while function was more satisfactory
after allograft-prosthetic composite reconstruction. In the
study, we have been able to show that prosthetic recon-
struction and reconstruction with recycled pasteurized
autograft are similar in terms of their local recurrence and
metastasis, while the incidence of revisions was higher for
patients with prosthetic reconstruction.
In our previous study [14], we treated malignant bone
tumors of the distal tibiae with “en bloc” intra-articular
excision and ankle arthrodesis using recycled pasteur-
ized autograft, the nonunion rate was 54.5% (6/11). In
the present study, the nonunion rate was 25.0% (4/16).
Although the characteristics of these two groups are
not quite equal to compare, the nonunion rate in the
present study was lower, which may be attributed to
the recycled pasteurized autograft combined with a
non-vascularised fibula autograft. However, the non-
union rate was much higher than other reports. Potter
Bk et al. [1] reported only one patient (5.9%) developed
nonunion in 17 patients with osteoarticular reconstruction
after humeral tumor excision. In van de Sande et al’s study
[5], the nonunion rate was 15.4% (2/13). In Aponte-Tinaohe different types of reconstruction techniques with revision
Figure 8 Kaplan-Meier disease-specific survival of patients.
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imal humerus osteoarticular allograft after tumor excision
and none became nonuion.
We found 5-year Kaplan-Meier implant survival esti-
mates, with revision for any reason as the end point, of
80.6% and 68.8% for the group P and group B, respectively.
In previous reports of osteoarticular graft survivorship,
Getty and Peabody [6] found 68% Kaplan-Meier graft
survival at 5 years, and Potter et al. [1] reported 56%
Kaplan-Meier graft survival at 5 year. However, the 5-year
Kaplan-Meier prothesis survival was 100% in Potter et al’s
study [1], which was much higher than ours.
In Manfrini et al. study [15], they suggested that free
fibular flaps will incorporate into the allograft. Li et al.
[16] observed that abundant callus originated from the
outlayer of the fibula that union the fibula with the host
bone and allograft together. Pasteurized autogenous bones
are similar to allografts, in that both possess bone induction
ability and bone conductive ability [14]. Sugiura et al.
[17] reviewed pasteurized intercalary autogenous bone graft
combined with a fibula graft and stated that the addition of
a fibula graft seems to promote the theoretically anticipated
remodeling process. Our results indicate pasteurized inter-
calary autogenous bone graft combined with a fibula graft
is a useful reconstruction method for large bone defects
after resection of osteosarcoma in the humors.
We note several limitations in this study. First, this
study was retrospective and the study period included a
relatively broad time frame. As such, patient selection
between each group was not standardized. Reconstruc-
tions with recycled pasteurized autograft generally were
performed earlier during the study period as we became
increasingly aware of the high nonunion rate associatedwith this technique. Second, the numbers of patients in
each cohort and the study as a whole are relatively small
but these numbers are comparable or greater than in
previous reports. Third, though only five patients devel-
oped local recurrence and eight patients developed pul-
monary metastasis at current follow-up, a longer follow up
is required since these were malignant lesions with a possi-
bility of late disease recurrence. Fourth, a non-vascularised
fibula autograft not a vascularised fibula autograft was
adopted in the study, a vascularised fibula autograft maybe
better for bone union.
Conclusions
The study could show that prosthetic reconstruction
and reconstruction with recycled pasteurized autograft
are similar in terms of their local recurrence and metas-
tasis, while the incidence of revisions was higher for pa-
tients with prosthetic reconstruction.
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